GB201521751D0 - Novel uses - Google Patents

Novel uses

Info

Publication number
GB201521751D0
GB201521751D0 GBGB1521751.6A GB201521751A GB201521751D0 GB 201521751 D0 GB201521751 D0 GB 201521751D0 GB 201521751 A GB201521751 A GB 201521751A GB 201521751 D0 GB201521751 D0 GB 201521751D0
Authority
GB
United Kingdom
Prior art keywords
novel uses
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1521751.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Priority to GBGB1521751.6A priority Critical patent/GB201521751D0/en
Publication of GB201521751D0 publication Critical patent/GB201521751D0/en
Priority to PL16813020.1T priority patent/PL3386506T3/pl
Priority to PT168130201T priority patent/PT3386506T/pt
Priority to CN201680072639.8A priority patent/CN108472288B/zh
Priority to CN202410102663.8A priority patent/CN118267386A/zh
Priority to JP2018529633A priority patent/JP7149847B2/ja
Priority to HRP20240497TT priority patent/HRP20240497T1/hr
Priority to KR1020187017088A priority patent/KR102812887B1/ko
Priority to MX2018007074A priority patent/MX385578B/es
Priority to HUE16813020A priority patent/HUE066879T2/hu
Priority to US16/060,714 priority patent/US11147813B2/en
Priority to SG11201804123VA priority patent/SG11201804123VA/en
Priority to EA201891377A priority patent/EA038059B1/ru
Priority to DK16813020.1T priority patent/DK3386506T3/da
Priority to FIEP16813020.1T priority patent/FI3386506T3/fi
Priority to BR112018011700-5A priority patent/BR112018011700B1/pt
Priority to AU2016367239A priority patent/AU2016367239B2/en
Priority to PCT/GB2016/053879 priority patent/WO2017098254A1/en
Priority to ES16813020T priority patent/ES2974902T3/es
Priority to CA3005302A priority patent/CA3005302A1/en
Priority to EP16813020.1A priority patent/EP3386506B1/en
Priority to IL259717A priority patent/IL259717B/en
Priority to US17/472,493 priority patent/US11944623B2/en
Priority to JP2022106247A priority patent/JP2022141699A/ja
Priority to US18/427,639 priority patent/US20250017925A1/en
Priority to JP2024154042A priority patent/JP2025003958A/ja
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/315Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB1521751.6A 2015-12-10 2015-12-10 Novel uses Ceased GB201521751D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
EP16813020.1A EP3386506B1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain
EA201891377A EA038059B1 (ru) 2015-12-10 2016-12-09 Применение модуляторов каналов kv3.1/kv3.2/kv3.3 для лечения боли
FIEP16813020.1T FI3386506T3 (fi) 2015-12-10 2016-12-09 Kv3-kanavien modulaattoreita kivun hoitamiseksi
CN201680072639.8A CN108472288B (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛
CN202410102663.8A CN118267386A (zh) 2015-12-10 2016-12-09 Kv3通道的调节剂用于治疗疼痛
JP2018529633A JP7149847B2 (ja) 2015-12-10 2016-12-09 疼痛を治療するためのkv3チャネルのモジュレーター
HRP20240497TT HRP20240497T1 (hr) 2015-12-10 2016-12-09 Modulatori kv3 kanala za liječenje boli
KR1020187017088A KR102812887B1 (ko) 2015-12-10 2016-12-09 통증을 치료하기 위한 kv3 채널의 조절제
MX2018007074A MX385578B (es) 2015-12-10 2016-12-09 Moduladores de canales de kv3 para tratar dolor.
HUE16813020A HUE066879T2 (hu) 2015-12-10 2016-12-09 A Kv3-csatornák modulátorai a fájdalom kezelésére
US16/060,714 US11147813B2 (en) 2015-12-10 2016-12-09 Modulators of KV3 channels to treat pain
SG11201804123VA SG11201804123VA (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain
PL16813020.1T PL3386506T3 (pl) 2015-12-10 2016-12-09 Modulatory kanałów Kv3 do leczenia bólu
DK16813020.1T DK3386506T3 (da) 2015-12-10 2016-12-09 Modulatorer af kv3-kanaler til at behandle smerte
PT168130201T PT3386506T (pt) 2015-12-10 2016-12-09 Moduladores de canais kv3 para tratar dor
BR112018011700-5A BR112018011700B1 (pt) 2015-12-10 2016-12-09 Moduladores de canais de kv3 para tratar dor
AU2016367239A AU2016367239B2 (en) 2015-12-10 2016-12-09 Modulators of Kv3 channels to treat pain
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain
ES16813020T ES2974902T3 (es) 2015-12-10 2016-12-09 Moduladores de los canales Kv3 para tratar el dolor
CA3005302A CA3005302A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain
IL259717A IL259717B (en) 2015-12-10 2018-05-30 modulators of kv3 channels for pain management
US17/472,493 US11944623B2 (en) 2015-12-10 2021-09-10 Modulators of Kv3 channels to treat pain
JP2022106247A JP2022141699A (ja) 2015-12-10 2022-06-30 疼痛を治療するためのkv3チャネルのモジュレーター
US18/427,639 US20250017925A1 (en) 2015-12-10 2024-01-30 Modulators of kv3 channels to treat pain
JP2024154042A JP2025003958A (ja) 2015-12-10 2024-09-06 疼痛を治療するためのkv3チャネルのモジュレーター

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses

Publications (1)

Publication Number Publication Date
GB201521751D0 true GB201521751D0 (en) 2016-01-27

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1521751.6A Ceased GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses

Country Status (21)

Country Link
US (3) US11147813B2 (enExample)
EP (1) EP3386506B1 (enExample)
JP (3) JP7149847B2 (enExample)
KR (1) KR102812887B1 (enExample)
CN (2) CN108472288B (enExample)
AU (1) AU2016367239B2 (enExample)
BR (1) BR112018011700B1 (enExample)
CA (1) CA3005302A1 (enExample)
DK (1) DK3386506T3 (enExample)
EA (1) EA038059B1 (enExample)
ES (1) ES2974902T3 (enExample)
FI (1) FI3386506T3 (enExample)
GB (1) GB201521751D0 (enExample)
HR (1) HRP20240497T1 (enExample)
HU (1) HUE066879T2 (enExample)
IL (1) IL259717B (enExample)
MX (1) MX385578B (enExample)
PL (1) PL3386506T3 (enExample)
PT (1) PT3386506T (enExample)
SG (1) SG11201804123VA (enExample)
WO (1) WO2017098254A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
FI3867247T3 (fi) * 2018-10-16 2024-10-30 Autifony Therapeutics Ltd Uusia yhdisteitä
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
AR116898A1 (es) * 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
AU2019390907B2 (en) 2018-11-30 2025-05-08 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of epilepsy
KR20220139923A (ko) 2020-02-06 2022-10-17 오티포니 세라피틱스 리미티드 Kv3 조절제
US20240327406A1 (en) 2021-08-10 2024-10-03 Autifony Therapeutics Limited Potassium channel modulators
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110033149A (ko) 2008-06-06 2011-03-30 유씨비 파마, 에스.에이. 시클로부톡시기를 포함하는 화합물
KR101735675B1 (ko) * 2009-12-11 2017-05-15 오티포니 세라피틱스 리미티드 이미다졸리딘디온 유도체
US9346790B2 (en) 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
IN2014CN04014A (enExample) * 2011-12-06 2015-07-10 Autifony Therapeutics Ltd
BR112014028991A2 (pt) * 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
WO2013175211A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
HUE066879T2 (hu) 2024-09-28
BR112018011700A2 (pt) 2018-11-27
EP3386506B1 (en) 2024-01-24
IL259717B (en) 2021-05-31
EP3386506A1 (en) 2018-10-17
ES2974902T3 (es) 2024-07-02
PL3386506T3 (pl) 2024-06-03
CN108472288A (zh) 2018-08-31
AU2016367239A1 (en) 2018-06-07
IL259717A (en) 2018-07-31
CN118267386A (zh) 2024-07-02
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
WO2017098254A1 (en) 2017-06-15
US11944623B2 (en) 2024-04-02
PT3386506T (pt) 2024-03-28
MX2018007074A (es) 2018-12-12
JP2025003958A (ja) 2025-01-14
US20250017925A1 (en) 2025-01-16
US20190000848A1 (en) 2019-01-03
BR112018011700B1 (pt) 2023-12-26
KR102812887B1 (ko) 2025-05-26
CN108472288B (zh) 2024-05-28
DK3386506T3 (da) 2024-05-06
AU2016367239B2 (en) 2020-07-09
JP7149847B2 (ja) 2022-10-07
HRP20240497T1 (hr) 2024-08-16
JP2022141699A (ja) 2022-09-29
CA3005302A1 (en) 2017-06-15
KR20180097549A (ko) 2018-08-31
SG11201804123VA (en) 2018-06-28
FI3386506T3 (fi) 2024-04-23
US11147813B2 (en) 2021-10-19
JP2019506367A (ja) 2019-03-07
EA038059B1 (ru) 2021-06-30
EA201891377A1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
DK3320033T3 (en) Polyethylenterephthalat-depolymerisering
IL253740B (en) Freezing needle
GB201502152D0 (en) Novel use
GB201509326D0 (en) Novel use
DK3373882T3 (en) Patientisolator
GB201521751D0 (en) Novel uses
LT3059221T (lt) Pentil-nonilo tereftalatai
IL253635A0 (en) Cyclopropanebenzofuranyl pyridopyrazinedione type compounds
GB201513158D0 (en) Microdosimeter
GB201509499D0 (en) Zkd
PL3393990T3 (pl) Środek wiążący peg
GB201515850D0 (en) Glycommetics
GB2541249B (en) Hole-saw
GB201520225D0 (en) Novel use
AU366552S (en) Nutblock
GB201521340D0 (en) Snapshop
GB201520664D0 (en) LAMHinge
PL3365601T3 (pl) Krematoria
GB201517489D0 (en) NoFlat
GB201513803D0 (en) Novel Use
GB201514277D0 (en) Tippex
GB201510628D0 (en) Novel use
PH32015000643S1 (en) Ballpen
GB201512651D0 (en) Base-Match
GB201512381D0 (en) Coffeelate

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)